Air fresheners which are used for clean refreshing house or car may smells sweet but very few people understand how bad air fresheners are for their health. Science has confirmed that though air freshener smells sweet but they may cause lung cancer. People with asthma or allergies may want to avoid air fresheners and other chemicals used to spread fragrant scents through their homes, and their doctors should be aware of the hazards.
In a recent reversal, operations abroad are hampering profit.
Ranbaxy Laboratories exclusive launch of generic anti-herpes Valtrex (valacyclovir hydrochloride) tablets in the US will help a listed Indian drug company, Hyderabad-based Avon Organics.
Mexico City has announced plans for what it hopes will be a world-class centre for biomedical and nano-medical research. To be called Campus Biometropolis, the city hopes the new centre will attract investment and become an "engine for the transformation" of Mexico's economy.
Dan Vasella, the chief executive of Swiss firm Novartis, which has been struggling for the last five years to secure the patent rights in India on Glivec, its therapy for a rare form of blood cancer called chronic myeloid leukemia, has spoken again on the alleged gaps in the Indian patent system.
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts.
Companies seem to be hesitating in moving ahead as they wait for further improvements in the global economy. However, Frost & Sullivan believes that the best CEOs are already planning how their businesses will take advantage of the growth opportunities presented by the rebound.
The list of drug majors scouting for a suitable buy in India is long. But this time, the attraction is: India as a market, and not merely as an inexpensive destination to source and produce products, say consultants and lawyers observing the increased merger and acquisition (M&A) activity seen in the pharmaceutical space.
Pfizer Ltd, the Indian subsidiary of the world’s largest drug maker Pfizer Inc., is making an aggressive play in the Indian generics or off-patent drugs market.
India emerging as a big global destination for contract manufacturing, unlike R&D outsourcing
Growing awareness and increased investments lead to growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements sector, reveals Frost & Sullivan
Last week, Lupin, Matrix Laboratories and Unichem Laboratories’ UK subsidiary Niche Generics figured in the list of companies under investigation by the European Commission for “knowingly delaying” the generic launch of a cardiovascular drug, Perindopril, by teaming with the innovator of the drug, Laboratories Servier. The European Commission said it would probe anti-trust violations against these manufacturers.
In a shot in the arm for Indian drugmakers, the trade and competition commissions of the European Union (EU), the US, and Italy are cracking down on unfair competition practices adopted by multinational pharma companies to extend their monopoly and delay low-cost generics from reaching consumers.
Among all industries, the pharmaceutical sector will perhaps benefit the most from the withdrawal of the ill-conceived fringe benefit tax, as it spends a minimum of 15 per cent of its turnover on medical representatives and sales promotion.
Multinational drug makers seem hell bent upon forcing the government to alter the patent regulations in their favour.
Pharmaceutical sector striding forward on greenhouse gas emissions.
Increased use of generic drugs helped the US healthcare system save billions of dollars over the last decade.
The Indian pharma industry welcomed the UPA's return to power with a decisive mandate saying it would enable formation of a stable government and carry forward economic reforms, while raising hopes that the Centre would frame policies that will support the sector.
Sun Pharmaceutical, a Mumbai-based Rs 3350 crore pharmaceutical giant and India's fastest growing international speciality pharma company, has received award in Outstanding Pharmaceuticals, Healthcare & Life Sciences category at the 3rd DHL and CNBC-TV18 International Trade Awards 2008-2009. These awards recognise the efforts of organisations and individuals who have driven India's growth engine in global trade and taken 'Brand India' to the world.
The UK government budget delivered in the gloom of the recession has provided good news for the industry, according to its leaders.
